Citral Is Renoprotective for Focal Segmental Glomerulosclerosis by Inhibiting Oxidative Stress and Apoptosis and Activating Nrf2 Pathway in Mice

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yang, Shun Min ^a,b   Hua, Kuo Feng ^c   Lin, Yu Chuan ^a   Chen, Ann ^b   Chang, Jia Ming ^d   Kuoping Chao, Louis ^e   Ho, Chen Lung ^f   Ka, Shuk Man ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL ILAN UNIVERSITY   (Taiwan)

^d DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f TAIWAN FORESTRY RESEARCH INSTITUTE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CITRAL; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; EPITHELIUM HYPERPLASIA; FOCAL GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYALINE DEGENERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION;

ANIMALS; APOPTOSIS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; INFLAMMATION; MACROPHAGES; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MONOTERPENES; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; PODOCYTES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84884253453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074871     Document Type: Article

References (74)

1. Cravedi P, Kopp JB, Remuzzi G, (2013) Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. Am J Transplant, 13: 266-74. PubMed: 23312002.
2. D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, et al. (2012) Association of Histologic Variants in FSGS Clinical Trial with Presenting Features and Outcomes. Clin J Am Soc Nephrol.
3. McCarthy ET, Sharma M, Savin VJ, (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115-2121. doi:10.2215/CJN.03800609. PubMed: 20966123.
4. Abrantes MM, Cardoso LS, Lima EM, Penido Silva JM, Diniz JS, et al. (2006) Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis. Pediatr Nephrol 21: 1003-1012. doi:10.1007/s00467-006-0138-y. PubMed: 16773414.
5. Sozeri B, Mir S, Mutlubas F, Sen S, (2010) The long-term results of pediatric patients with primary focal and segmental glomerulosclerosis. Saudi J Kidney Dis Transpl 21: 87-92. PubMed: 20061699.
6. Korbet SM, (2012) Treatment of primary FSGS in adults. J Am Soc Nephrol 23: 1769-1776. doi:10.1681/ASN.2012040389. PubMed: 22997260.
7. Pani A, (2012) Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev.
8. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, et al. (2008) Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev CD: pp. 003233. PubMed: 18646090.
9. Korbet SM, (2000) The treatment of primary focal segmental glomerulosclerosis. Ren Fail 22: 685-696. doi:10.1081/JDI-100101956. PubMed: 11104158.
10. Goumenos DS, Tsagalis G, El Nahas AM, Shortland JR, Davlouros P, et al. (2006) Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 104: c75-c82. doi:10.1159/000093993. PubMed: 16785738.
11. Stirling CM, (2006) Focal segmental glomerulosclerosis--does treatment work? Nephron Clin Pract 104: c83-c84. doi:10.1159/000093994. PubMed: 16785739.
12. Passerini P, Scolari F, Frasca GM, Leoni A, Venturelli C, et al. (2009) [Controversial issues in the Giornale Italiano di Nefrologia: how to treat patients with focal segmental glomerular sclerosis]. G Ital Nefrol 26: 563-576. PubMed: 19802802.
13. Bruschi M, Candiano G, Della Ciana L, Petretto A, Santucci L, et al. (2011) Analysis of the oxido-redox status of plasma proteins. Technology advances for clinical applications. J Chromatogr B Anal Technol Biomed Life Sci 879: 1338-1344. doi:10.1016/j.jchromb.2010.11.030.
14. Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, et al. (2007) Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol 18: 799-810. doi:10.1681/ASN.2006090965. PubMed: 17287427.
15. Tsai PY, Ka SM, Chao TK, Chang JM, Lin SH, et al. (2011) Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 50: 1503-1516. doi:10.1016/j.freeradbiomed.2011.02.029. PubMed: 21376112.
16. Benz K, Büttner M, Dittrich K, Campean V, Dötsch J, et al. (2010) Characterisation of renal immune cell infiltrates in children with nephrotic syndrome. Pediatr Nephrol 25: 1291-1298. doi:10.1007/s00467-010-1507-0. PubMed: 20386928.
17. Muñoz M, Rincón J, Pedreañez A, Viera N, Hernández-Fonseca JP, et al. (2011) Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. J Renin Angiotensin Aldosterone Syst 12: 404-412. doi:10.1177/1470320311410092. PubMed: 21705470.
18. Wang Y, Wang YP, Tay YC, Harris DC, (2001) Role of CD8(+) cells in the progression of murine adriamycin nephropathy. Kidney Int 59: 941-949. doi:10.1046/j.1523-1755.2001.00577.x. PubMed: 11231349.
19. Benchimol C, (2003) Focal segmental glomerulosclerosis: pathogenesis and treatment. Curr Opin Pediatr 15: 171-180. doi:10.1097/00008480-200304000-00006. PubMed: 12640274.
20. Ozbek E, (2012) Induction of oxidative stress in kidney. Int J Nephrol(2012): pp. 465897. PubMed: 22577546.
21. Rojas-Rivera J, Ortiz A, Egido J, (2012) Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int J Nephrol(2012): pp. 321714. PubMed: 22701794.
22. Kim HJ, Vaziri ND, (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298: F662-F671. doi:10.1152/ajprenal.00421.2009. PubMed: 20007347.
23. Liu GC, Fang F, Zhou J, Koulajian K, Yang S, et al. (2012) Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse. Diabetologia 55: 2522-2532. doi:10.1007/s00125-012-2586-1. PubMed: 22653270.
24. Shen B, Hagiwara M, Yao YY, Chao L, Chao J, (2008) Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 51: 1358-1365. doi:10.1161/HYPERTENSIONAHA.107.108514. PubMed: 18391098.
25. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, et al. (2005) Nrf2, a multi-organ protector? FASEB J 19: 1061-1066. doi:10.1096/fj.04-2591hyp. PubMed: 15985529.
26. Nguyen T, Nioi P, Pickett CB, (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295. doi:10.1074/jbc.R900010200. PubMed: 19182219.
27. Wilmes A, Crean D, Aydin S, Pfaller W, Jennings P, et al. (2011) Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol Vitro 25: 613-622. doi:10.1016/j.tiv.2010.12.009. PubMed: 21172416.
28. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, et al. (2011) Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33: 469-476. doi:10.1159/000327599. PubMed: 21508635.
29. Thornalley PJ, Rabbani N, (2012) Dietary and synthetic activators of the antistress gene response in treatment of renal disease. J Ren Nutr 22: 195-202. doi:10.1053/j.jrn.2011.10.012. PubMed: 22200442.
30. Ruiz S, Pergola PE, Zager RA, Vaziri ND, (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int, 83: 1029-41. PubMed: 23325084.
31. Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin PY, et al. (2012) NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 23: 1967-1976. doi:10.1681/ASN.2012040373. PubMed: 23100220.
32. Oh CJ, Kim JY, Choi YK, Kim HJ, Jeong JY, et al. (2012) Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. PLOS ONE 7: e45870. doi:10.1371/journal.pone.0045870. PubMed: 23056222.
33. Cheel J, Theoduloz C, Rodríguez J, Schmeda-Hirschmann G, (2005) Free radical scavengers and antioxidants from Lemongrass (Cymbopogon citratus (DC.) Stapf.). J Agric Food Chem 53: 2511-2517. doi:10.1021/jf0479766. PubMed: 15796587.
34. Barroso MF, Noronha JP, Delerue-Matos C, Oliveira MB, (2011) Flavored waters: influence of ingredients on antioxidant capacity and terpenoid profile by HS-SPME/GC-MS. J Agric Food Chem 59: 5062-5072. doi:10.1021/jf1048244. PubMed: 21462928.
35. Lee HJ, Jeong HS, Kim DJ, Noh YH, Yuk DY, et al. (2008) Inhibitory effect of citral on NO production by suppression of iNOS expression and NF-kappa B activation in RAW264.7 cells. Arch Pharm Res 31: 342-349. doi:10.1007/s12272-001-1162-0. PubMed: 18409048.
36. Bachiega TF, Sforcin JM, (2011) Lemongrass and citral effect on cytokines production by murine macrophages. J Ethnopharmacol 137: 909-913. doi:10.1016/j.jep.2011.07.021. PubMed: 21782918.
37. Lin CT, Chen CJ, Lin TY, Tung JC, Wang SY, (2008) Anti-inflammation activity of fruit essential oil from Cinnamomum insularimontanum Hayata. Bioresour Technol 99: 8783-8787. doi:10.1016/j.biortech.2008.04.041. PubMed: 18513962.
38. Ortiz MI, González-García MP, Ponce-Monter HA, Castañeda-Hernández G, Aguilar-Robles P, (2010) Synergistic effect of the interaction between naproxen and citral on inflammation in rats. Phytomedicine 18: 74-79. doi:10.1016/j.phymed.2010.05.009. PubMed: 20637575.
39. Shui HA, Ka SM, Yang SM, Lin YF, Lo YF, et al. (2007) Osteopontin as an injury marker expressing in epithelial hyperplasia lesions helpful in prognosis of focal segmental glomerulosclerosis. Transl Res 150: 216-222. doi:10.1016/j.trsl.2007.04.003. PubMed: 17900509.
40. Pouchert CJ, Campbell JR, (1974) The Aldrich library of NMR spectra. Aldrich Chemical Co.
41. Shui HA, Ka SM, Lin JC, Lee JH, Jin JS, et al. (2006) Fibronectin in blood invokes the development of focal segmental glomerulosclerosis in mouse model. Nephrol Dial Transplant 21: 1794-1802. doi:10.1093/ndt/gfl113. PubMed: 16574682.
42. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, et al. (2012) Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappa B (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 55: 509-519. doi:10.1007/s00125-011-2364-5. PubMed: 22086159.
43. Ka SM, Hsieh TT, Lin SH, Yang SS, Wu CC, et al. (2011) Decoy receptor 3 inhibits renal mononuclear leukocyte infiltration and apoptosis and prevents progression of IgA nephropathy in mice. Am J Physiol Renal Physiol 301: F1218-F1230. doi:10.1152/ajprenal.00050.2011. PubMed: 21900455.
44. Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, et al. (2011) Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 51: 744-754. doi:10.1016/j.freeradbiomed.2011.05.016. PubMed: 21641991.
45. Yang B, Johnson TS, Thomas GL, Watson PF, Wagner B, et al. (2002) A shift in the Bax/Bcl-2 balance may activate caspase-3 and modulate apoptosis in experimental glomerulonephritis. Kidney Int 62: 1301-1313. doi:10.1111/j.1523-1755.2002.kid587.x. PubMed: 12234300.
46. Liao PC, Chien SC, Ho CL, Wang EI, Lee SC, et al. (2010) Osthole regulates inflammatory mediator expression through modulating NF-kappaB, mitogen-activated protein kinases, protein kinase C, and reactive oxygen species. J Agric Food Chem 58: 10445-10451. doi:10.1021/jf102812t. PubMed: 20839800.
47. Schachter AD, Strehlau J, Zurakowski D, Vasconcellos L, Kim YS, et al. (2000) Increased nuclear factor-kappaB and angiotensinogen gene expression in posttransplant recurrent focal segmental glomerulosclerosis. Transplantation 70: 1107-1110. doi:10.1097/00007890-200010150-00021. PubMed: 11045652.
48. Watson D, Zheng G, Wu H, Wang YM, Wang Y, et al. (2009) CCL2 DNA vaccine to treat renal disease. Int J Biochem Cell Biol 41: 729-732. doi:10.1016/j.biocel.2008.04.028. PubMed: 18768165.
49. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Kołodziejczyk Z, (2011) Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol 45: 52-59. doi:10.3109/00365599.2010.526140. PubMed: 21034351.
50. Wang Y, Wang Y, Feng X, Bao S, Yi S, et al. (2001) Depletion of CD4(+) T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney Int 59: 975-984. doi:10.1046/j.1523-1755.2001.059003975.x. PubMed: 11231352.
51. Wang Y, Wang Y, Cai Q, Zheng G, Lee VWS, et al. (2008) By homing to the kidney, activated macrophages potently exacerbate renal injury. Am J Pathol 172: 1491-1499. doi:10.2353/ajpath.2008.070825. PubMed: 18467704.
52. Wyburn KR, Chadban SJ, Kwan T, Alexander SI, Wu H, (2013) Interleukin-18 binding protein therapy is protective in adriamycin nephropathy. Am J Physiol Renal Physiol 304: F68-F76. doi:10.1152/ajprenal.00669.2011. PubMed: 23097468.
53. Su SC, Hua KF, Lee H, Chao LK, Tan SK, et al. (2006) LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. Clin Chim Acta 374: 106-115. doi:10.1016/j.cca.2006.05.045. PubMed: 16899235.
54. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, et al. (2011) Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60: 3055-3066. doi:10.2337/db11-0807. PubMed: 22025779.
55. Li W, Khor TO, Xu C, Shen G, Jeong WS, et al. (2008) Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 76: 1485-1489. doi:10.1016/j.bcp.2008.07.017. PubMed: 18694732.
56. Kim JH, Choi YK, Lee KS, Cho DH, Baek YY, et al. (2012) Functional dissection of Nrf2-dependent phase II genes in vascular inflammation and endotoxic injury using Keap1 siRNA. Free Radic Biol Med 53: 629-640. doi:10.1016/j.freeradbiomed.2012.04.019. PubMed: 22609006.
57. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, et al. (2012) Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 23: 1663-1673. doi:10.1681/ASN.2012050457. PubMed: 22859857.
58. Zoja C, Corna D, Nava V, Locatelli M, Abbate M, et al. (2013) Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 304: F808-F819. doi:10.1152/ajpcell.zh0-7226.corr.2013. PubMed: 23136004.
59. Liby KT, Yore MM, Sporn MB, (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369. doi:10.1038/nrc2129. PubMed: 17446857.
60. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, et al. (2011) New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545. doi:10.1021/np100826q. PubMed: 21309592.
61. Pedruzzi LM, Stockler-Pinto MB, Leite M Jr., Mafra D, (2012) Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? Biochimie 94: 2461-2466. doi:10.1016/j.biochi.2012.07.015. PubMed: 22874821.
62. Therrien FJ, Agharazii M, Lebel M, Larivière R, (2012) Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure. Am J Nephrol 36: 151-161. doi:10.1159/000340033. PubMed: 22813949.
63. Zhang K, (2010) Integration of ER stress, oxidative stress and the inflammatory response in health and disease. Int J Clin Exp Med 3: 33-40. PubMed: 20369038.
64. Grande MT, Perez-Barriocanal F, Lopez-Novoa JM, (2010) Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J Inflamm (Lond) 7: 19. doi:10.1186/1476-9255-7-19.
65. Queisser N, Schupp N, (2012) Aldosterone, oxidative stress, and NF-kappaB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med 53: 314-327. doi:10.1016/j.freeradbiomed.2012.05.011. PubMed: 22609249.
66. Akcay A, Nguyen Q, Edelstein CL, (2009) Mediators of inflammation in acute kidney injury. Mediators Inflamm, 2009(2009): 137072. PubMed: 20182538.
67. Robinson JM, (2009) Phagocytic leukocytes and reactive oxygen species. Histochem Cell Biol 131: 465-469. doi:10.1007/s00418-009-0565-5. PubMed: 19224236.
68. Anders HJ, Ryu M, (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925. doi:10.1038/ki.2011.217. PubMed: 21814171.
69. Liu S, Jia Z, Zhou L, Liu Y, Ling H, et al. (2013) Nitro-Oleic Acid Protects Against Adriamycin-Induced Nephropathy in Mice. Am J Physiol Renal Physiol. PubMed: 23486011.
70. Circu ML, Aw TY, (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762. doi:10.1016/j.freeradbiomed.2009.12.022. PubMed: 20045723.
71. Erkan E, Garcia CD, Patterson LT, Mishra J, Mitsnefes MM, et al. (2005) Induction of renal tubular cell apoptosis in focal segmental glomerulosclerosis: roles of proteinuria and Fas-dependent pathways. J Am Soc Nephrol 16: 398-407. doi:10.1681/ASN.2003100861. PubMed: 15601749.
72. Ory V, Fan Q, Hamdaoui N, Zhang SY, Desvaux D, et al. (2012) c-mip down-regulates NF-kappaB activity and promotes apoptosis in podocytes. Am J Pathol 180: 2284-2292. doi:10.1016/j.ajpath.2012.02.008. PubMed: 22507836.
73. Niture SK, Jaiswal AK, (2012) Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med, 57: 119-31. PubMed: 23275004.
74. Niture SK, Jaiswal AK, (2012) Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873-9886. doi:10.1074/jbc.M111.312694. PubMed: 22275372.